**ADAM-17: a novel therapeutic target for triple negative breast cancer**


An incorrect version of Figure 4 was used in the original version. The correct version is below. The authors apologize for the error.

**Figure 4.** Barcharts illustrating the effect of PF-548 (1 µM) alone or in combination with pan-HER inhibitors (neratinib, afatinib) on growth of 4 breast cancer cell lines (A–D), as determined by MTT assay. EGFR inhibitors (gefitinib) and chemotherapeutics (cisplatin, carboplatin, 5-fluorouracil and doxorubicin), were all used at a concentration of 1 µM, doxorubicin at a concentration of 0.05 µM and neratinib at a concentration of 0.5 µM. Additional cell lines are shown in Supplementary Figure S2, available at *Annals of Oncology* online. *P <0.05 versus PF-548 alone, Student’s paired t-test.*